To showcase the power of our technology we are currently developing conjugate VLX101 for application in treating a wide range of autoimmune diseases.

Additionally we have recently added a similar conjugate targeting proliferative disease.




We are actively looking for strong partners for co-development of our assets. If you are interested, please do not hesitate to get in touch.

Our science, your benefit.


Find out more how we can support you in developing cutting-edge biologics.

Learn more